NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 5.57% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 5.52% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 5.43% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 4.50% |
| ARGX | argenx NV ADR | Healthcare | Biotechnology | 3.90% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 3.84% |
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 3.70% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | Drug Manufacturers - General | 3.47% |
| INCY | Incyte Corporation | Healthcare | Biotechnology | 3.41% |
| 4568 | Daiichi Sankyo Co. Ltd. | Healthcare | Drug Manufacturers - General | 3.13% |
| BPMC | Blueprint Medicines Corp | Healthcare | Biotechnology | 3.10% |
| IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
| MREO | Mereo BioPharma Group PLC ADR | Healthcare | Biotechnology | 2.81% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 2.77% |
| BGNE | BeiGene Ltd | Healthcare | Biotechnology | 2.51% |
| EXEL | Exelixis Inc | Healthcare | Biotechnology | 2.32% |
| CRSP | Crispr Therapeutics AG | Healthcare | Biotechnology | 2.31% |
| EXAS | EXACT Sciences Corporation | Healthcare | Diagnostics & Research | 2.26% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 2.21% |
| AGIO | Agios Pharm | Healthcare | Biotechnology | 2.19% |